AI Article Synopsis
- The study focuses on a 29-year-old male patient with traumatic brain injury (TBI) from a vehicle accident, who received stem cell transplantation (SCT) to address ongoing deficiencies.
- The treatment involved six doses of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) delivered through intrathecal, intramuscular, and intravenous routes over six months.
- Results showed improvements in speech, cognition, memory, and fine motor skills, with no major side effects, highlighting SCT's potential as a treatment for TBI.
Article Abstract
Aim: To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies.
Material And Methods: This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago. The participant received six doses of intrathecal, intramuscular, and intravenous transplantation of Wharton?s jellv-derived mesenchymal stem cells (WJ-MSCs) at a goal dose of 1xl0 < sup > 6 < /sup > / kg respectively for each route of administration for six months.
Results: No important negative effects were reported. The patients? speech, cognitive, memory and fine motor skills were improved. The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG).
Conclusion: SCT can have a promising future as a medical approach in recurrent TBI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5137/1019-5149.JTN.31732-20.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!